EUCTR2006-000828-14-AT进行中（未招募）不适用
A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With and Without Ribavirin (Copegus®) in Subjects with Hepatitis C - Phase2 Study of VX-950,Pegasys(peginterferon alfa-2a,Peg-IFN) & Copegus(ribavirin,RBV) in HepatitisC
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male and female subjects, 18-65 years of age, inclusive.
- •- Genotype 1 (confirmed by standard testing), chronic hepatitis C, confirmed by detectable plasma HCV RNA.
- •- Judged to be in good health on the basis of medical history and physical examination (including vital signs and ECG), with any chronic medical conditions under stable medical control.
- •- Both Screening Visit 1 and Screening Visit 2 laboratory values must be within protocl-specified laboratory reference ranges.
- •- Must agree to use 2 methods of contraception that are highly effective, one barrier method (condom or diaphragm with spermicidal jelly) with a second method such as oral contraceptives, hormonal implant, injectable contraceptive, an intrauterine device or surgical sterilization (i.e. vasectomy or female surgical sterilization), during and for 24 weeks after the last dose of study medication (unless the subject is a woman of documented non-child-bearing potential). Female subjects and female partners of male subjects must use the same precautions. Male subjects must not father a child while on study, and for 24 weeks after the last dose of the study medications.
- •- Female subjects must have a negative pregnancy test at all visits (screening and pre-dose Day 1) before the first dose of study drugs.
- •- Willing to refrain from the concomitant use of any medications, substances or foods noted in Section 12.8 of the protocol.
- •- Willing to initiate SOC (Peg-IFN and RBV) off-study at the conclusion of study drug dosing, if subjects have detectable virus or relapse.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Received any approved or investigational drug or drug regimen for the treatment of hepatitis C.
- •- Any medical contraindications to Peg-IFN or RBV therapy.
- •- Decompensated liver disease as shown by screening laboratory results.
- •- Any other cause of significant liver disease in addition to hepatitis C.
- •- Diagnosed or suspected hepatocellular carcinoma.
- •- Histologic evidence of hepatic cirrhosis on any liver biopsy. Most recent liver biopsy must be within 2 years before Study Day 1.
- •- Alcohol abuse or excessive use (in the opinion of the investigator, as judged by medical history) in the last 12 months.
- •- Hypersensitivity to tartrazine (yellow dye #5).
- •- Men whose female partners are pregnant.
研究者
相似试验
进行中（未招募）
不适用
A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With and Without Ribavirin (Copegus®) in Subjects with Hepatitis C - Phase 2 Study of VX-950, Pegasys, and Copegus in Hepatitis CEUCTR2006-000828-14-DEVertex Pharmaceuticals Incorporated320
进行中（未招募）
1 期
A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With and Without Ribavirin (Copegus®) in Subjects with Hepatitis C - Phase 2 Study of VX-950, Pegasys, and Copegus in Hepatitis CHepatitis C virus (HCV) infectionMedDRA version: 8.1 Level: LLT Classification code 10019744 Term: Hepatitis CEUCTR2006-000828-14-GBVertex Pharmaceuticals Incorporated320
进行中（未招募）
不适用
A multi-centre phase II controlled study of Vx-001 in Non Small Cell Lung Cancer (NSCLC)EUCTR2006-005032-25-GRVaxon Biotech225
撤回
不适用
STUDY OF VGX-3100 DELIVERED IM FOLLOWED BY ELECTROPORATION (EP) FOR THE TREATMENT OF CIN 2/3 OR CIN 3 WITH HPV 16 OR 18Diseases of The genitoruinary systemKCT0000284Inovio148
进行中（未招募）
不适用
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3EUCTR2012-001334-33-EEInovio Pharmaceuticals, Inc.148